BidaskClub upgraded shares of Epizyme (NASDAQ:EPZM) from a hold rating to a buy rating in a report released on Tuesday morning.

Other analysts have also recently issued reports about the stock. Cowen restated a buy rating on shares of Epizyme in a research note on Monday, September 24th. Zacks Investment Research upgraded shares of Epizyme from a hold rating to a buy rating and set a $8.25 target price for the company in a research note on Tuesday, December 4th. ValuEngine upgraded shares of Epizyme from a sell rating to a hold rating in a research note on Saturday, December 15th. Oppenheimer set a $27.00 target price on shares of Epizyme and gave the company a buy rating in a research note on Thursday, November 15th. Finally, Leerink Swann assumed coverage on shares of Epizyme in a research note on Monday, September 24th. They issued a market perform rating and a $11.00 target price for the company. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $20.00.

NASDAQ EPZM traded down $0.07 on Tuesday, hitting $9.49. 25,538 shares of the company’s stock traded hands, compared to its average volume of 1,214,046. Epizyme has a 1-year low of $5.14 and a 1-year high of $21.40. The stock has a market cap of $763.18 million, a price-to-earnings ratio of -4.41 and a beta of 2.04.

Epizyme (NASDAQ:EPZM) last announced its quarterly earnings data on Friday, November 2nd. The biopharmaceutical company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.07. Sell-side analysts forecast that Epizyme will post -1.93 earnings per share for the current fiscal year.

A number of large investors have recently bought and sold shares of EPZM. Shell Asset Management Co. purchased a new stake in shares of Epizyme during the third quarter worth $198,000. BB&T Securities LLC grew its holdings in shares of Epizyme by 45.5% during the second quarter. BB&T Securities LLC now owns 16,000 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 5,000 shares in the last quarter. BlueMountain Capital Management LLC purchased a new stake in shares of Epizyme during the second quarter worth $320,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Epizyme during the second quarter worth $345,000. Finally, MetLife Investment Advisors LLC grew its holdings in shares of Epizyme by 50.5% during the third quarter. MetLife Investment Advisors LLC now owns 37,738 shares of the biopharmaceutical company’s stock worth $400,000 after buying an additional 12,663 shares in the last quarter. Institutional investors own 73.27% of the company’s stock.

About Epizyme

Epizyme, Inc, a clinical stage biopharmaceutical company, discovers and develops novel epigenetic medicines for patients with cancer and other diseases in the United States. Its product candidates include tazemetostat, an inhibitor of the EZH2, which is in Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial in elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function,; and Phase Ib/II clinical trial for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer, as well as Phase II clinical trial in adult patients with ovarian cancer.

Further Reading: What is intrinsic value?

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.